Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Megan L. Baker(Yale University), Dennis G. Moledina(Yale University), Navid Hafez(Smilow Cancer Hospital), Jason Weinstein(Yale University), Anushree C. Shirali(Medical Protective), Chirag R. Parikh(College of Medicine & JNM Hospital), Mark A. Perazella(Yale University), Lloyd G. Cantley(Yale University), Michael Simonov(Yale University), Nazlı Dizman(City Of Hope National Medical Center), Yu Yamamoto, Harriet M. Kluger(Yale Cancer Center), Jeffrey M. Testani(Yale University), F. Perry Wilson(Yale University)
Cited by 42
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2
|New England Journal of Medicine|2020|1k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k